clinical trial · NCT05288504
A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.
Avalo Therapeutics, Inc.·phase2·completed·n = 91
Non-Eosinophilic AsthmaAVTX-002Placebo
brief summary
The primary objective of this study is to evaluate the efficacy of AVTX-002 compared with placebo in patients with poorly controlled non-eosinophilic asthma (NEA).
started
Feb 24, 2022
primary completion
May 11, 2023
completion
May 11, 2023
last updated
Sep 5, 2024
official title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol